7 Hills Pharma is a clinical-stage company advancing first-in-class small molecules leveraging a novel mechanism of action, pioneered by 7HP founders, to safely enhance the effectiveness of immunotherapies against treatment-resistant solid tumors, with no added toxicities. Our platform of selective integrin activators optimize multiple rate-limiting immune cell adhesion events to overcome resistance and drive a productive anti-tumor immune response. Our unique mechanism of action attacks a fundamental pathway of tumor immune evasion. In a Phase Ib/IIa clinical trial testing alintegimod, our first clinical-stage molecule, in combination with sequential dual checkpoint blockade against aPD-1-resistant solid tumors, we have so far treated 12 patients, with encouraging early biomarker observations, disease control, and a partial response. The Phase Ib data readout is expected mid-2026.